Josh Schimmer
Stock Analyst at Cantor Fitzgerald
(3.56)
# 837
Out of 4,944 analysts
133
Total ratings
46.61%
Success rate
6.05%
Average return
Main Sectors:
Stocks Rated by Josh Schimmer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RCKT Rocket Pharmaceuticals | Maintains: Overweight | $10 → $8 | $2.91 | +174.91% | 6 | Aug 8, 2025 | |
| BBIO BridgeBio Pharma | Reiterates: Overweight | $95 | $49.09 | +93.52% | 12 | Jul 29, 2025 | |
| TRVI Trevi Therapeutics | Initiates: Overweight | $25 | $7.33 | +241.06% | 1 | Jul 1, 2025 | |
| CMPS COMPASS Pathways | Downgrades: In-Line | $11 → $6 | $4.22 | +42.18% | 2 | Jun 23, 2025 | |
| SEPN Septerna | Maintains: Overweight | $20 → $25 | $11.20 | +123.21% | 3 | May 16, 2025 | |
| ASND Ascendis Pharma | Maintains: Outperform | $260 → $280 | $196.02 | +42.85% | 4 | May 2, 2025 | |
| CGON CG Oncology | Reiterates: Overweight | $75 | $24.98 | +200.24% | 4 | Apr 28, 2025 | |
| AARD Aardvark Therapeutics | Reiterates: Overweight | $50 | $10.04 | +398.01% | 2 | Apr 1, 2025 | |
| ARTV Artiva Biotherapeutics | Maintains: Overweight | $23 → $20 | $2.47 | +709.72% | 2 | Mar 25, 2025 | |
| KRYS Krystal Biotech | Reiterates: Overweight | $215 | $143.62 | +49.70% | 5 | Feb 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $5 | $2.36 | +111.86% | 4 | Dec 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $200 | $24.27 | +724.06% | 6 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $25 | $21.43 | +16.66% | 1 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.47 | - | 5 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $30 | $16.66 | +80.07% | 4 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $6.15 | - | 3 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $2.00 | - | 2 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $90 | $28.48 | +216.01% | 6 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $2.85 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $122.00 | - | 5 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $17.80 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $14.89 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $2.43 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $72.50 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 | $0.50 | +2,877.96% | 3 | Aug 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $53 | $46.23 | +14.64% | 5 | Aug 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $65 | $35.99 | +80.61% | 3 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $60 | $64.72 | -7.29% | 5 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $50 | $1.33 | +3,659.40% | 1 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $43 → $5 | $2.63 | +90.11% | 2 | Nov 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $11 | $1.56 | +605.13% | 2 | Jun 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $140 → $130 | $128.89 | +0.86% | 1 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $760 | $556.56 | +36.55% | 2 | Oct 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $15 | $13.01 | +15.30% | 1 | Mar 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $55 | $7.29 | +654.98% | 1 | Feb 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $2.03 | +1,381.48% | 1 | Dec 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | n/a | $1.12 | - | 4 | Dec 9, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $8.10 | - | 3 | Feb 25, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $222 → $250 | $359.00 | -30.36% | 4 | Nov 16, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $81.61 | - | 2 | Jun 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | n/a | $41.41 | - | 2 | May 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | n/a | $3.39 | - | 2 | Mar 12, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | n/a | $13.22 | - | 2 | Mar 12, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $22 | $14.30 | +53.85% | 1 | Nov 7, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $11.92 | - | 2 | Aug 17, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $56.86 | - | 1 | Aug 17, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $95 | $198.64 | -52.17% | 1 | Aug 17, 2017 |
Rocket Pharmaceuticals
Aug 8, 2025
Maintains: Overweight
Price Target: $10 → $8
Current: $2.91
Upside: +174.91%
BridgeBio Pharma
Jul 29, 2025
Reiterates: Overweight
Price Target: $95
Current: $49.09
Upside: +93.52%
Trevi Therapeutics
Jul 1, 2025
Initiates: Overweight
Price Target: $25
Current: $7.33
Upside: +241.06%
COMPASS Pathways
Jun 23, 2025
Downgrades: In-Line
Price Target: $11 → $6
Current: $4.22
Upside: +42.18%
Septerna
May 16, 2025
Maintains: Overweight
Price Target: $20 → $25
Current: $11.20
Upside: +123.21%
Ascendis Pharma
May 2, 2025
Maintains: Outperform
Price Target: $260 → $280
Current: $196.02
Upside: +42.85%
CG Oncology
Apr 28, 2025
Reiterates: Overweight
Price Target: $75
Current: $24.98
Upside: +200.24%
Aardvark Therapeutics
Apr 1, 2025
Reiterates: Overweight
Price Target: $50
Current: $10.04
Upside: +398.01%
Artiva Biotherapeutics
Mar 25, 2025
Maintains: Overweight
Price Target: $23 → $20
Current: $2.47
Upside: +709.72%
Krystal Biotech
Feb 20, 2025
Reiterates: Overweight
Price Target: $215
Current: $143.62
Upside: +49.70%
Dec 20, 2024
Downgrades: In-Line
Price Target: $5
Current: $2.36
Upside: +111.86%
Dec 11, 2024
Reiterates: Overweight
Price Target: $200
Current: $24.27
Upside: +724.06%
Dec 11, 2024
Reiterates: Overweight
Price Target: $25
Current: $21.43
Upside: +16.66%
Dec 11, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.47
Upside: -
Oct 8, 2024
Reiterates: Overweight
Price Target: $30
Current: $16.66
Upside: +80.07%
Sep 23, 2024
Downgrades: Neutral
Price Target: n/a
Current: $6.15
Upside: -
Sep 17, 2024
Reiterates: Overweight
Price Target: n/a
Current: $2.00
Upside: -
Sep 16, 2024
Reiterates: Overweight
Price Target: $90
Current: $28.48
Upside: +216.01%
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $2.85
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $122.00
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $17.80
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $14.89
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $2.43
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $72.50
Upside: -
Aug 26, 2024
Maintains: Outperform
Price Target: $15
Current: $0.50
Upside: +2,877.96%
Aug 26, 2024
Maintains: Outperform
Price Target: $54 → $53
Current: $46.23
Upside: +14.64%
Aug 9, 2024
Reiterates: Overweight
Price Target: $65
Current: $35.99
Upside: +80.61%
Aug 8, 2024
Maintains: Overweight
Price Target: $50 → $60
Current: $64.72
Upside: -7.29%
Jun 21, 2024
Reiterates: Overweight
Price Target: $50
Current: $1.33
Upside: +3,659.40%
Nov 10, 2023
Downgrades: In-Line
Price Target: $43 → $5
Current: $2.63
Upside: +90.11%
Jun 6, 2023
Maintains: Outperform
Price Target: $20 → $11
Current: $1.56
Upside: +605.13%
Nov 14, 2022
Downgrades: In-Line
Price Target: $140 → $130
Current: $128.89
Upside: +0.86%
Oct 17, 2022
Downgrades: In-Line
Price Target: $760
Current: $556.56
Upside: +36.55%
Mar 15, 2022
Initiates: Outperform
Price Target: $15
Current: $13.01
Upside: +15.30%
Feb 2, 2021
Initiates: Outperform
Price Target: $55
Current: $7.29
Upside: +654.98%
Dec 29, 2020
Initiates: Outperform
Price Target: $30
Current: $2.03
Upside: +1,381.48%
Dec 9, 2019
Downgrades: In-Line
Price Target: n/a
Current: $1.12
Upside: -
Feb 25, 2019
Upgrades: Outperform
Price Target: n/a
Current: $8.10
Upside: -
Nov 16, 2018
Upgrades: Outperform
Price Target: $222 → $250
Current: $359.00
Upside: -30.36%
Jun 11, 2018
Upgrades: Outperform
Price Target: n/a
Current: $81.61
Upside: -
May 8, 2018
Downgrades: In-Line
Price Target: n/a
Current: $41.41
Upside: -
Mar 12, 2018
Downgrades: In-Line
Price Target: n/a
Current: $3.39
Upside: -
Mar 12, 2018
Downgrades: In-Line
Price Target: n/a
Current: $13.22
Upside: -
Nov 7, 2017
Initiates: Outperform
Price Target: $22
Current: $14.30
Upside: +53.85%
Aug 17, 2017
Initiates: Outperform
Price Target: n/a
Current: $11.92
Upside: -
Aug 17, 2017
Initiates: Outperform
Price Target: n/a
Current: $56.86
Upside: -
Aug 17, 2017
Initiates: Outperform
Price Target: $95
Current: $198.64
Upside: -52.17%